Aldeyra Therapeutics
ALDX
24 hedge funds and large institutions have $38M invested in Aldeyra Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
20% more funds holding
Funds holding: 20 → 24 (+4)
16% more capital invested
Capital invested by funds: $32.8M → $38M (+$5.13M)
3.45% more ownership
Funds ownership: 48.78% → 52.23% (+3.5%)
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$4.87M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.45M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.54M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$925K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$771K |
Top Sellers
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$760K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$669K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$476K |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$60.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17.5K |
ALDX Hedge Fund Activity: Q1 2017 in Review
24 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2017, worth a combined $38M — up 16% from $32.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALDX positions and 2 closed out — a net gain of 7 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $4.87M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $760K sold.
- 24 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2017, up from 20 in Q4 2016.
- Funds reported $38M of Aldeyra Therapeutics stock for Q1 2017, up 16% quarter-over-quarter.
- 9 funds opened new Aldeyra Therapeutics positions in Q1 2017 and 2 closed out, a net change of +7 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2017 was Perceptive Advisors, an estimated $4.87M added.
- The largest Aldeyra Therapeutics seller in Q1 2017 was Baker Bros. Advisors, an estimated $760K sold.
Based on aggregated 13F filings for Q1 2017.